NEWGENIVF GROUP LIMITED (NASDAQ: NIVF)

1. Introduction

NEWGENIVF Group Limited (ticker: NIVF) is a NASDAQ-listed provider of fertility services in Asia. As of June 2, 2025, its share price was USD 3.5093, representing an increase of 73.73% on that trading day, with a trading volume of 10,591,591 shares. The company operates under its brand First Fertility across multiple Asian markets, offering In Vitro Fertilization (IVF), surrogacy, and family-balancing treatments.

2. Corporate Profile

• Management Experience
  The leadership team, led by Founder, Chairman, and CEO Alfred Siu Wing Fung, has over a decade of experience in the fertility industry.

• Clinical Network
  NEWGENIVF operates clinics in:

  • Bangkok, Thailand
  • Phnom Penh, Cambodia
  • Bishkek, Kyrgyzstan

• Staff Composition
  Each clinic employs IVF doctors, embryologists, nurses, and patient-care assistants trained in reproductive technologies.

3. Developments and News

3.1 Termination of Proposed Reverse Merger (March 31, 2025)

On March 31, 2025, NEWGENIVF announced the termination of its binding term sheet with European Wellness Investment Holdings Limited (EWIHL). EWIHL was intended to acquire approximately 61.6% of equity via a reverse merger, contingent upon the delivery of audited financial statements for 2023–2024 by the same date. The failure to meet this condition allowed NewGen to terminate the agreement at no cost.

3.2 Acquisition of MicroSort Technology (February 28, 2025)

On February 28, 2025, NEWGENIVF completed its acquisition of MicroSort Reproductive Technology. This acquisition enhances the company’s service offerings related to genetic sex-selection and sperm-sorting technologies.

3.3 SEC Filings

• Form F-1/A Amendments (May 20 & May 29, 2025): Registration statements for foreign private issuers outlining financial disclosures and risk factors (available via SEC.gov).
• Form 6-K Report (June 2, 2025): Routine report of a foreign issuer, primarily detailing foreign issuer regulatory compliance without additional financial data.

4. Financial and Strategic Analysis

4.1 Share Performance (As of June 2, 2025)

Metric	Value
Share Price	USD 3.5093
Intraday Market Cap	USD 2.6 million
Volume	10,591,591 shares
52-Week Range	USD 1.09–32.80
Beta (5Y Monthly)	0.13

4.2 Key Financial Metrics (TTM)

Metric	Value
Revenue	USD 5.43 million
Net Income	–USD 525,000
Profit Margin	–9.66%
Diluted EPS	–293.10
Price/Sales	0.00
Enterprise Value/Revenue	0.75
EV/EBITDA	169.58

4.3 Balance Sheet Highlights

• Total Cash (MRQ): USD 1.53 million
• Total Debt (as of February 2025): USD 50,000
• Net Asset Surplus: Transitioned from a USD 7 million deficit (September 2024) to a USD 10 million surplus (February 2025), indicating a net increase of USD 17 million.
• Net Asset Value per Share: USD 2.16

4.4 Strategic Focus

• Expanding service capabilities through acquisitions, such as MicroSort.
• Maintaining core IVF and surrogacy operations in Asia.
• Evaluating potential partnerships and mergers that align with long-term growth objectives.

5. Market Position and Industry Context

• Geographic Footprint: Thailand, Cambodia, Kyrgyzstan—markets with increasing demand for fertility treatments.
• Service Range: IVF, surrogacy, egg and sperm donation, genetic sex-selection, egg-freezing.
• Competitive Landscape: Operates alongside regional fertility clinics, differentiating via integrated service offerings and technological acquisitions.
• Regulatory Environment: Subject to healthcare regulations in each jurisdiction; compliance and audited reporting are critical.

6. tl;dr

• On March 31, 2025, NEWGENIVF terminated its proposed reverse merger with EWIHL after failing to meet due diligence deadlines.
• On February 28, 2025, the company completed its acquisition of MicroSort, enhancing its reproductive technology capabilities.
• From September 2024 to February 2025, net assets increased by USD 17 million, transforming a USD 7 million deficit into a USD 10 million surplus; net asset value per share reached USD 2.16 with debt at USD 50,000.
• As of June 2, 2025, the share price is USD 3.5093, reflecting a 73.73% increase intraday, with an intraday market cap of USD 2.6 million.
• Future prospects center on leveraging acquired technologies and exploring further strategic transactions to enhance shareholder value.